Parkinson’s disease affects more than 1.1 million people in the U.S., according to the Parkinson’s Foundation.
A new study helps explain why a promising class of cancer drugs has often failed to meet expectations in clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results